efanesoctocog alfa (BIVV001)
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Von Willebrand's Disease (VWD)
Conditions
Von Willebrand's Disease (VWD)
Trial Timeline
May 3, 2021 → Dec 20, 2022
NCT ID
NCT04770935About efanesoctocog alfa (BIVV001)
efanesoctocog alfa (BIVV001) is a phase 1 stage product being developed by Sanofi for Von Willebrand's Disease (VWD). The current trial status is completed. This product is registered under clinical trial identifier NCT04770935. Target conditions include Von Willebrand's Disease (VWD).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04770935 | Phase 1 | Completed |
| NCT04644575 | Phase 3 | Active |
| NCT04759131 | Phase 3 | Completed |
| NCT04161495 | Phase 3 | Completed |